HONG KONG – I-Mab Biopharma (Shanghai) Co. Ltd. out-licensed China rights to its long-acting glucagon-like peptide-1 (GLP-1) Fc protein, known as TG-103, to treat diabetes to CSPC Pharmaceutical Group Co. Ltd. for ¥150 million (US$21.7 million).
HONG KONG – In a deal involving up to $391.5 million, HKEX-listed Innovent Biologics Inc. (HKG:1801) in-licensed three clinical-stage assets from Incyte Corp. to develop and commercialize them in the Chinese mainland, Hong Kong, Macau and Taiwan.
HONG KONG – Chinese biosimilar maker Shanghai Henlius Biotech Inc. on Monday filed for an IPO on the Hong Kong Stock Exchange, making it the seventh pre-profit biotech firm in the listing queue, while four have gone public.
HONG KONG – HKEX-listed Innovent Biologics Inc. said its IBI-305 referencing Roche Holding AG's Avastin (bevacizumab) has met primary endpoints in two randomized, head-to-head trials, putting the company one step closer to bringing to market one of the first Avastin biosimilars approved in China.
HONG KONG – Chinese biosimilar maker Shanghai Henlius Biotech Inc. on Monday filed for an IPO on the Hong Kong Stock Exchange, making it the seventh pre-profit biotech firm in the listing queue, while four have gone public.
HONG KONG – HKEX-listed Innovent Biologics Inc. said its IBI-305 referencing Roche Holding AG's Avastin (bevacizumab) has met primary endpoints in two randomized, head-to-head trials, putting the company one step closer to bringing to market one of the first Avastin biosimilars approved in China.
HONG KONG – On its way to become the fifth firm listed in Hong Kong since the exchange opened to pre-profit biotechs, Shanghai Junshi Biosciences Co. Ltd. plans to raise HK$3.021.6 billion (US$386.7 million) by offering about 158.9 million shares. The IPO would help Junshi advance its core asset, JS-001 (toripalimab), a monoclonal antibody locked in a race to become China's first self-developed anti-PD-1 drug approved in the country.
HONG KONG – On its way to become the fifth firm listed in Hong Kong since the exchange opened to pre-profit biotechs, Shanghai Junshi Biosciences Co. Ltd. plans to raise HK$3.021.6 billion (US$386.7 million) by offering about 158.9 million shares. The IPO would help Junshi advance its core asset, JS-001 (toripalimab), a monoclonal antibody locked in a race to become China's first self-developed anti-PD-1 drug approved in the country.
TAIPEI, Taiwan – How to attract capital is a well-trod theme in the biopharma sector, but the best investors bring more than just money to the table, speakers noted during the Asia Pacific Biotech Investment Forum last week. The right kind of business know-how could help turn a company with a good idea and solid research into a unicorn, a startup with a valuation of $1 billion.
